帶狀皰疹疫苗市場機會、成長促進因素、產業趨勢分析與預測 2025 - 2034 年

2024 年全球帶狀皰疹疫苗市場估值為49 億美元，預計2025 年至2034 年將以10.1% 的複合年成長率強勁成長。對帶狀皰疹認知的提高預防和併發症。

對大眾（尤其是老年人）進行帶狀皰疹風險教育的努力極大地促進了疫苗的採用。衛生組織強調疫苗接種在減輕嚴重併發症（包括慢性疼痛）方面的好處。這些活動鼓勵採取積極主動的健康措施，特別是針對老年人及其照護人員，進一步推動市場擴張。

公共衛生運動和教育計劃顯著提高了人們尤其是老年人對帶狀皰疹風險的認知。衛生組織正在積極強調疫苗接種在預防疾病和最大程度地減少慢性疼痛的機會方面的重要性。因此，越來越多的老年人及其照護者選擇接種疫苗作為預防性保健措施，推動帶狀皰疹疫苗市場的擴張。

該市場按產品分為Shingrix、Zostavax和SKYZoster，其中Shingrix以2024年42億美元的收入引領市場。該疫苗的持久免疫力減少了頻繁加強接種的需要，增強了其作為一種經濟高效且可靠的選擇的吸引力。

依疫苗類型，市場分為重組疫苗和減毒活疫苗。重組疫苗在 2024 年佔據主導地位，預計到 2034 年將達到 113 億美元。它們的免疫持續時間較長，無需重複給藥，這使它們成為比減毒活疫苗更好的選擇。

北美帶狀皰疹疫苗市場到 2024 年將創造 27 億美元的收入。針對 50 歲及以上成年人接種帶狀皰疹疫苗的建議已被廣泛採用，並得到 Medicare 和私人保險公司提供的保險範圍的支持。人口老化和積極的健康措施進一步鞏固了該地區的市場地位。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 老年人口不斷增加
    • 疫苗開發的進展
    • 優惠報銷政策
    • 人們對帶狀皰疹及其併發症的認知不斷提高
  • 產業陷阱與挑戰
    • 嚴格的監管要求
• 成長潛力分析
• 監管環境
• 2023 年定價分析
• 管道分析
• 技術景觀
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2034 年

• 主要趨勢
• 欣格里克斯
• 佐斯塔瓦克斯
• 天空佐斯特

第 6 章：市場估計與預測：按疫苗類型，2021 - 2034 年

• 主要趨勢
• 重組疫苗
• 減毒活疫苗

第 7 章：市場估計與預測：按地區分類，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 8 章：公司簡介

• GSK plc
• Merck & Co.
• SK bioscience

The Global Shingles Vaccine Market was valued at USD 4.9 billion in 2024 and is projected to grow at a robust CAGR of 10.1% from 2025 to 2034. Key factors driving this growth include the increasing aging population, improved reimbursement frameworks, and heightened awareness about shingles prevention and complications.

Efforts to educate the public about shingles risks, particularly among older adults, have significantly boosted vaccine adoption. Health organizations are emphasizing the benefits of vaccination in mitigating severe complications, including chronic pain. These campaigns encourage proactive health measures, particularly among the elderly and their caregivers, further fueling the market expansion.

Public health campaigns and educational programs have significantly increased awareness of the risks posed by shingles, especially among older adults. Health organizations are proactively highlighting the importance of vaccination in preventing the disease and minimizing the chances of chronic pain. Consequently, a growing number of elderly individuals and their caregivers are choosing vaccination as a preventive healthcare step, driving the expansion of the shingles vaccine market.

The market is segmented by product into Shingrix, Zostavax, and SKYZoster, with Shingrix leading the market by generating USD 4.2 billion in revenue in 2024. Its recombinant formulation provides durable and effective protection, particularly for high-risk groups such as older adults. The vaccine's long-lasting immunity reduces the need for frequent boosters, enhancing its appeal as a cost-effective and reliable option.

By vaccine type, the market is categorized into recombinant and live attenuated vaccines. The recombinant vaccine segment dominated in 2024 and is forecasted to reach USD 11.3 billion by 2034. These vaccines demonstrate superior efficacy, offering 90% protection even among vulnerable populations. Their extended immunity duration eliminates the need for repeated doses, making them the preferred choice over live attenuated options.

North America shingles vaccine market generated USD 2.7 billion in 2024. This dominance is driven by high awareness levels, supportive healthcare policies, and strong public health advocacy. Recommendations for shingles vaccination for adults aged 50 and older have been widely adopted, supported by accessible insurance coverage through Medicare and private insurers. The aging demographic and proactive health initiatives further strengthen the region's market position.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising geriatric population
    • 3.2.1.2 Advancements in vaccine development
    • 3.2.1.3 Favourable reimbursement policies
    • 3.2.1.4 Growing awareness about shingles and its complications
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pricing analysis, 2023
• 3.6 Pipeline analysis
• 3.7 Technology landscape
• 3.8 Future market trends
• 3.9 Gap analysis
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Shingrix
• 5.3 Zostavax
• 5.4 SKYZoster

Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Recombinant vaccine
• 6.3 Live attenuated vaccine

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 GSK plc
• 8.2 Merck & Co.
• 8.3 SK bioscience